Nyrada (ASX:NYR) - CEO, James Bonnar
CEO, James Bonnar
Source: Perth Now
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Biotechnology company Nyrada (NYR) has appointed Charles River Laboratories to conduct preclinical studies in the US
  • The studies are used to evaluate safety and tolerability of its cholesterol-lowering drug candidate
  • The data will determine the safe starting dose for the first-in-human study
  • Nyrada (NYR) closed Tuesday at A$0.22 per share

Biotechnology company Nyrada has appointed Charles River Laboratories to conduct preclinical studies in the US on its cholesterol-lowering drug candidate.

Following the studies, a cholesterol-lowering trial will be held in Australia.

The studies are used to evaluate safety and tolerability of Nyrada’s drug in research models. Data will determine the safe starting dose for the Phase 1 first-in-human study.

Nyrada CEO James Bonnar said the company was excited to be advancing to the next phase of its program.

“There is considerable industry interest in the development of oral PCSK9 inhibitors and we remain confident that our oral drug candidate, taken as a pill, has the potential to provide an important alternative to expensive and inconvenient injectable PCSK9 inhibitor drugs.”

The Phase I study will be a first-in-human, double-blind, randomised, dose escalation design evaluating the safety, tolerability, and pharmacokinetics of Nyrada’s leading drug candidate in approximately 56 healthy volunteers aged 18 to 50 years.

Nyrada has filed a PCT patent application for new generation PCSK9 inhibitor compounds.

The company specialises in novel small molecule drugs to treat cardiovascular and neurological diseases.

Nyrada (NYR) last traded at A$0.22 per share at Tuesday’s market close.

NYR by the numbers
More From The Market Online
The Market Online Video

Market Close: Green lights up on ASX for Easter hunt go

The ASX200 closed the day in record territory - nearly a per cent up with every…

Week 13 Wrap: Easter bunny delivers new all time high for ASX200

Another week, another all time high. The ASX200 clocked 7,901pts on Thursday for the first time…

Market shrugs as Fisher & Paykel announces mass recall

Fisher & Paykel has initiated a voluntary limited recall of batches of Airvo 1 and my…
The Market Online Video

Market Update: ASX glows red hot with another hit record

The ASX200 is trading up, hitting a new high of 7901 point and eclipsing the last…